The investigation of temporal decision-making revealed an interesting aspect linked to the effects of the Afh mutation in our mice.
The presence of the JAK2 mutation in our case confirmed that the lesions represented skin involvement by a neoplastic myeloid proliferation and not compensatory extramedullary hematopoiesis.
There was no evidence of the L74V mutation in our study group in either the ZDV/ddI or ZDV/ddC combination therapy group.
We are all carriers of several such mutations, which do not harm us, but if combined with the same mutation in our partner, they create a risk that our child will be affected by a genetic disease.
These observations are backed by extensive literature that argue for the existence of somatic mutation in our genomes [12, 41, 67, 68].
It's our version of mutation, in our denatured, devolved state; generating and sifting among alternative bad options and landing on one that just might work out.
Therefore, we decided against using this mutation in our S. Typhi vaccine vectors.
In addition, there was no prevalent mutation in our patients nor a hg background apparently associated with the clinical phenotypes.
This is the most abundant mutation in our FMF cohort and is present in 70% of the patients.
However, the lack of significant association between miR-34c downregulation and p53 mutation in our current series indicate that additional influences are likely important in regulating miR-34c expression in high grade serous carcinomas.
Indeed, we could not match dbSNP and HGMD for these genes because of their different codon numbering, which explains why we could not find the aforementioned factor V Leiden mutation in our catalog of concurrent CVs.
